Improvements in cystic fibrosis lung disease and airway inflammation associated with etanercept therapy for rheumatoid arthritis: A case report

Lung

Volumn 190, Issue 5, 2012, Pages 579-581

  Visser, S ^a   Martin, M ^a   Serisier, D J ^a,b,c  

^a MATER ADULT HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Cystic fibrosis; Etanercept; Exacerbation; Lung function; Pulmonary; Sputum percent neutrophils; TNF a antagonist

Indexed keywords

CIPROFLOXACIN; COLISTIN; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; NAPROXEN; PREDNISOLONE; RHEUMATOID FACTOR;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BURKHOLDERIA; CASE REPORT; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; HOMOZYGOTE; HUMAN; INFECTION CONTROL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFLAMMATION; RHEUMATOID ARTHRITIS; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYNOVITIS; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUNG DISEASES; NEUTROPHILS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866735697     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9393-9     Document Type: Article

References (7)

1. Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918-951
2. Cohen-Cymberknoh M, Shoseyov D, Kerem E (2011) Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 183:1463-1471
3. Konstan MW, Doring G, Lands LC et al (2005) Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol 40(Suppl 28):125
4. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin Infect Dis 38:1261-1265
5. Curtis JR, Xi J, Patkar N et al (2007) Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumour necrosis factor antagonists. Arthritis Rheum 56:4226
6. Casserly B, Donat W (2009) Stabilization of lung function and clinical symptoms in a patient with cystic fibrosis (CF) after institution of infliximab: a monoclonal antibody that binds tumour necrosis factor alpha. Lung 187:149-152
7. Vincenzi F, Bizzarri B, Ghiselli A, de Angelis N, Fornaroli F, de Angelis GL (2010) Cystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab. World J Gastroenterol 16(15):1924-1927